Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients

Clinical Neurology and Neurosurgery

Volumn 139, Issue , 2015, Pages 35-40

  Pavsic, Katja ^a   Pelicon, Katarina ^a   Ledinek, Alenka Horvat ^b   Sega, Sasa ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

4 Aminopyridine; Arm hand function; Cognitive function; Depression; Fampridine; Mood; Multiple sclerosis; Quality of life

Indexed keywords

FAMPRIDINE; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARM MOVEMENT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COGNITION; DEPRESSION; FATIGUE; FEMALE; HAND FUNCTION; HUMAN; MALE; MOOD; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; PACED AUDITORY SERIAL ADDITION TEST; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; VISUAL ANALOG SCALE; WALKING; WALKING SPEED; AFFECT; CLINICAL TRIAL; DAILY LIFE ACTIVITY; EXERCISE TEST; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY; PSYCHOLOGY;

4-AMINOPYRIDINE; ACTIVITIES OF DAILY LIVING; ADULT; AFFECT; AGED; COGNITION; DEPRESSION; EXERCISE TEST; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POTASSIUM CHANNEL BLOCKERS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; WALKING;

EID: 84941287013     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2015.08.023     Document Type: Article

References (36)

1. J.L. Preiningerova, U. Baumhackl, T. Csepany, A. Czaplinski, F. Deisenhammer, T.P. Derfuss, and et al. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS) CNS Neurosci. Ther. 19 5 2013 302 306
2. EMA Human Medicines - Fampyra [Internet] 2014 European Medicines Agency London c1995 Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002097/human-med-001432.jsp&mid=WC0b01ac058001d125&murl=menus/medicines/medicines.jsp [accessed 01.05.14]
3. J. Dunn, and A. Blight Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis Curr. Med. Res. Opin. 27 7 2011 1415 1423
4. C.M. Chwieduk, and G.M. Keating Dalfampridine extended release: in multiple sclerosis CNS Drugs 24 10 2010 883 891
5. A.D. Goodman, T.R. Brown, L.B. Krupp, R.T. Schapiro, S.R. Schwid, R. Cohen, and et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial Lancet 373 9665 2009 732 738
6. A.D. Goodman, T.R. Brown, K.R. Edwards, L.B. Krupp, R.T. Schapiro, R. Cohen, and et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis Ann. Neurol. 68 4 2010 494 502
7. S. Sobek, R. Kempcke, T. Ziemssen, and T. Schultheis Impact of fampridine on fatigue, depression and cognition in multiple sclerosis p. 354 16th Congress of the European Federation of Neurological Societies (EFNS), September 8-11 2012 Blackwell Publishing Ltd. Stockholm, Sweden
8. T. Ruck, S. Bittner, O.J. Simon, K. Göbel, H. Wiendl, M. Schilling, and et al. Long-term effects of dalfampridine in patients with multiple sclerosis J. Neurol. Sci. 337 1-2 2014 18 24
9. J. Hobart, A.R. Blight, A. Goodman, F. Lynn, and N. Putzki Timed 25-Foot Walk: that improving direct record of 20% or greater is clinically meaningful and MS Neurology 80 16 2013 1509 1517
10. H.B. Jensen, M. Ravnborg, S. Mamoei, U. Dalgas, and E. Stenager Changes in cognition, arm function and lower body function after slow-release fampridine treatment Mult. Scler. 2014 pii: 1352458514533844. PMID: 24852920
11. I. Giordano, M. Bogdanow, H. Jacobi, K. Jahn, M. Minnerop, L. Schoels, and et al. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia J. Neurol. 260 8 2013 2175 2176
12. R. Schniepp, V. Jakl, M. Wuehr, J. Havla, T. Kümpfel, M. Dieterich, and et al. Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report Mult. Scler. 19 4 2013 506 508
13. P.M. Rossini, P. Pasqualetti, C. Pozzilli, M.G. Grasso, E. Millefiorini, A. Graceffa, and et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine Mult. Scler. 7 6 2001 354 358
14. A. Romani, R. Bergamaschi, E. Candeloro, E. Alfonsi, R. Callieco, and V. Cosi Fatigue and multiple sclerosis: multidimensional assessment and response to symptomatic treatment Mult. Scler. 10 4 2004 462 468
15. C.H. Polman, F.W. Bertelsmann, R. De Waal, H.A. van Diemen, B.M. Uitdehaag, A.C. van Loenen, and et al. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis Arch. Neurol. 51 11 1994 1136 1139
16. R.C. Smits, H.H. Emmen, F.W. Bertelsmann, B.M. Kulig, A.C. Van Loenen, and C.H. Polman The effects of 4-aminopyridine on cognitive function and patients with multiple sclerosis: a pilot study Neurology 44 9 1994 1701 1705
17. R. Macdonell, P.S. Sorensen, C. Pozzilli, G. Nagels, D. Laplaud, B. De Jong, and et al. Long-term prolonged-release fampridine treatment and health-related quality of life outcomes: nine-month interim analysis of the ENABLE study 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 18th Annual Conference of Rehabilitation in MS (RIMS), October 2-5 2013 SAGE Publications Ltd. Copenhagen, Denmark 291 292
18. B.L. Limone, M.F. Sidovar, and C.I. Coleman Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients Health Qual. Life Outcomes 11 1 2013 105
19. J.S. Fischer, A.J. Jak, J.E. Kniker, R.A. Rudick, and G. Cutter Multiple Sclerosis Functional Composite (MSFC): Administration and Scoring Manual [Internet] 2001 National Multiple Sclerosis Society Available from http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/10-2-3-31-MSFC-Manual-and-Forms.pdf [accessed 22.03.14]
20. C. Lewis, and K. Shaw Benefits of the 2-Minute Walk Test [Internet] 2005 Available from http://physical-therapy.advanceweb.com/Article/Benefits-of-the-2-Minute-Walk-Test.aspx [accessed 01.05.14]
21. P.G. Ritvo, J.S. Fisher, D.M. Miller, H. Andrews, D.W. Paty, and N.G. LaRocca Multiple Sclerosis Quality of Life Inventory: A User's Manual [Internet] 1997 National Multiple Sclerosis Society New York Available from: http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQLI-A-User-s-Manual.pdf [accessed 22.03.14]
22. N. Gusi, P.R. Olivares, and R. Rajendram The EQ-5D health-related quality of life questionnaire VR Preedy, RR Watson, Handbook of Disease Burdens and Quality of Life Measures [Internet] 2010 Springer New York New York, NY 87 99 Available from: http://link.springer.com/referenceworkentry/10.1007%2F978-0-387-78665-0-5 [accessed 09.04.14]
23. V. Rupel, and M. Ogorevc The EQ-5D health states value set for Slovenia Zdrav. Var. 51 2012 128 140
24. A.D. Goodman, T.R. Brown, J.A. Cohen, L.B. Krupp, R. Schapiro, S.R. Schwid, and et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis Neurology 71 15 2008 1134 1141
25. I. Baert, J. Freeman, T. Smedal, U. Dalgas, A. Romberg, A. Kalron, and et al. Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European Multicenter Study Neurorehabil. Neural. Repair 28 7 2014 621 631
26. F. Bethoux, and S. Bennett Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice? Int. J. MS Care 13 1 2011 4 14
27. P. Feys, B. Bibby, A. Romberg, C. Santoyo, B. Gebara, B.M. De Noordhout, and et al. Within-day variability on short and long walking tests in persons with multiple sclerosis J. Neurol. Sci. 338 1-2 2014 183 187
28. A.D. Goodman, J.A. Cohen, A. Cross, and et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study Mult. Scler. 13 3 2007 357 368
29. J. Claassen, R. Spiegel, R. Kalla, M. Faldon, C. Kennard, C. Danchaivijitr, and et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus - effects on slow phase eye velocity, postural stability, locomotion and symptoms J. Neurol. Neurosurg. Psychiatry 84 12 2013 1392 1399
30. F.A. Davis, D. Stefoski, and J. Rush Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis Ann. Neurol. 27 2 1990 186 192
31. D. Stefoski, F.A. Davis, M. Faut, and C.L. Schauf 4-Aminopyridine improves clinical signs in multiple sclerosis Ann. Neurol. 21 1 1987 71 77
32. H.A. Van Diemen, C.H. Polman, T.M. Van Dongen, and et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study Ann. Neurol. 32 2 1992 123 130
33. K. Hayes Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis Neuropsychiatr. Dis. Treat. 2011 229 239
34. T.J. Braley, and R.D. Chervin Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment Sleep 33 8 2010 1061 1067
35. S.W. Kinsinger, E. Lattie, and D.C. Mohr Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis Neuropsychology 24 5 2010 573 580
36. A.J. Mitchell, J. Benito-León, J.M. González, and J. Rivera-Navarro Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing Lancet Neurol. 4 9 2005 556 566